Novel therapeutic agents for B-cell lymphoma: developing rational combinations

[Guest guest]

BlankBlood, 3 February 2011, Vol. 117, No. 5, pp. 1453-1462.

Novel therapeutic agents for B-cell lymphoma: developing rational combinations

Craig B. er1, and M. Ansell2

1 Division of Hematology and Oncology, Mayo Clinic Arizona, sdale, AZ; and

2 Division of Hematology, Mayo Clinic Rochester, Rochester, MN

Several novel targeted therapies have recently emerged as active in the

treatment of non-Hodgkin lymphoma, including small molecules that inhibit

critical signaling pathways, promote apoptotic mechanisms, or modulate the tumor

microenvironment. Other new agents target novel cell surface receptors or

promote DNA damage. Although most of these drugs have single-agent activity,

none have sufficient activity to be used alone. This article reviews the utility

and potential role of these new agents in the treatment of non-Hodgkin lymphoma

with a specific focus on data that highlight how these agents may be

incorporated into current standard treatment approaches.